Trial Profile

A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Survodutide (Primary)
Indications Obesity
Focus Proof of concept; Therapeutic Use
Sponsors Boehringer Ingelheim

Most Recent Events

19 Mar 2025 Results of subgroup analysis by age assessing baseline BMI in people with a BMI ≥27 kg/m2 published in the Diabetes, Obesity and Metabolism
16 May 2024 According to a Zealand Pharma media release, the topline results will be presented at the European Association for the Study of the Liver (EASL) congress in Milan, Italy on June 7, 2024.
16 May 2024 Results presented in the Zealand Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com